LyGenesis Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $19M

  • Investors
  • 5

LyGenesis General Information

Description

Developer of a cell therapy technology designed to facilitate organ regeneration and transplant. The company's technology is focused on liver regeneration for patients with end-stage liver disease which uses lymph nodes as bioreactors and outpatient endoscopic ultrasound for transplantation of donor cells, enabling surgeons to regrow functioning organs within a patient's own body.

Contact Information

Website
www.lygenesis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1710 Murray Avenue
  • Suite 200
  • Pittsburgh, PA 15217
  • United States
+1 (412)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 1710 Murray Avenue
  • Suite 200
  • Pittsburgh, PA 15217
  • United States
+1 (412)

LyGenesis Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LyGenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A2) 24-Oct-2023 $19M Completed Clinical Trials - Phase 2
6. Merger/Acquisition 23-Jul-2021 Cancelled Clinical Trials - Phase 2
5. Accelerator/Incubator 01-Jan-2022 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 30-Dec-2020 Completed Clinical Trials - Phase 2
3. Early Stage VC 21-Oct-2019 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 09-May-2018 $3M $3M Completed Clinical Trials - Phase 1
1. Grant Completed Clinical Trials - Phase 1
To view LyGenesis’s complete valuation and funding history, request access »

LyGenesis Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view LyGenesis’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

LyGenesis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LyGenesis Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Prime Movers Lab Venture Capital Minority
University of Pittsburgh Innovation Institute Accelerator/Incubator
Longevity Vision Fund Venture Capital Minority
Juvenescence VC-Backed Company Minority
National Institutes of Health Government
To view LyGenesis’s complete investors history, request access »

Ready to get started?

Request a free trial

LyGenesis FAQs

  • When was LyGenesis founded?

    LyGenesis was founded in 2017.

  • Where is LyGenesis headquartered?

    LyGenesis is headquartered in Pittsburgh, PA.

  • What is the size of LyGenesis?

    LyGenesis has 7 total employees.

  • What industry is LyGenesis in?

    LyGenesis’s primary industry is Biotechnology.

  • Is LyGenesis a private or public company?

    LyGenesis is a Private company.

  • What is LyGenesis’s current revenue?

    The current revenue for LyGenesis is .

  • How much funding has LyGenesis raised over time?

    LyGenesis has raised $37.3M.

  • Who are LyGenesis’s investors?

    Prime Movers Lab, University of Pittsburgh Innovation Institute, Longevity Vision Fund, Juvenescence, and National Institutes of Health have invested in LyGenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »